User:Mr. Ibrahem/Sparsentan
 | |
| Clinical data | |
|---|---|
| Trade names | Filspari |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Endothelin and angiotensin II receptor blocker[1] |
| Legal status | |
| Legal status | |
Sparsentan, sold under the brand name Filspari, is a medication used to treat primary immunoglobulin A nephropathy.[1] Specifically it is used to reduce protein in the urine.[1] As of 2023, it is unclear if it affects long term kidney function.[1] It is taken by mouth.[1]
Common side effects include low blood pressure, swelling of the legs, high potassium, and low red blood cells.[1] Severe side effects may include liver problems.[1] Use in pregnancy may harm the baby.[1] It is an endothelin and angiotensin II receptor blocker.[1]
Sparsentan was approved for medical use in the United States in 2023.[1] It is estimated to cost about 170,000 USD per year in the United States as of 2023.[2]
References[edit]
- ^ a b c d e f g h i j k l m n "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Archived from the original on 7 March 2023. Retrieved 6 March 2023.
- ^ "February 2023 decisions expected from the FDA". Prime Therapeutics LLC. Archived from the original on 27 January 2023. Retrieved 24 May 2023.